Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy

Area of Science:

• Immunology
• Virology
• Oncology

Background:

• Effective cancer treatment requires overcoming tumor cell resistance to death and stimulating host antitumor immunity.
• Oncolytic viruses offer a promising approach by selectively killing tumor cells and eliciting immune responses.
• Challenges include the development of antiviral immunity and tumor-intrinsic defenses against repeated single-virus administration.

Purpose of the Study:

• To investigate if alternating immunologically distinct oncolytic viruses can circumvent antiviral immune responses and tumor defenses.
• To evaluate the efficacy of alternating adenovirus and vaccinia virus therapy in virus-resistant preclinical cancer models.

Main Methods:

• Utilized two distinct oncolytic viruses: adenovirus and vaccinia virus.
• Administered alternating injections of these viruses in two established virus-resistant animal cancer models.
• Monitored and analyzed the induction of antiviral immune responses and innate cellular defenses.

Main Results:

• Alternating adenovirus and vaccinia virus injections significantly delayed the induction of antiviral immune responses.
• This therapeutic strategy also postponed the onset of innate cellular defense mechanisms in the tumor microenvironment.
• Demonstrated a substantial delay in the development of resistance to oncolytic virotherapy.

Conclusions:

• Alternating oncolytic virus therapy with distinct agents like adenovirus and vaccinia virus is a viable strategy to overcome treatment resistance.
• This approach holds promise for enhancing the clinical efficacy of oncolytic virotherapy in cancer patients.
• Supports further clinical development of heterologous oncolytic virus combinations for cancer treatment.